Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

PHASE1TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

September 10, 2021

Study Completion Date

September 10, 2021

Conditions
Obesity
Interventions
DRUG

AMG 171

2 SAD cohorts of 8 subjects per cohort randomized 3:1 in Part A; 1 cohort of 8 subjects 3:1 ratio in Part B; and 24 subjects enrolled into 1 of 3 cohorts with 8 subjects randomized to receive 2 to 3 consecutive doses (titration) 3:1 ratio in Part C.

DRUG

Placebo

AMG 171 placebo

Trial Locations (3)

33014

Clinical Pharmacology of Miami, LLC, Miami

92780

Orange County Research Center, Tustin

92801

Anaheim Clinical Trials, Anaheim

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT04199351 - Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity | Biotech Hunter | Biotech Hunter